x
ServiziMenu principaleHome
Home > Sponsors & Exhibition > Sponsored satellite symposia
Print

Sponsored satellite symposia

Daiichi Sankyo/AstraZeneca sponsored satellite symposium
A team approach to the treatment of patients with HER2-postive metastatic breast cancer

 

On-demand session (duration: 01h15):

Welcome and meeting objectives
Véronique Diéras, FR

A patient in your clinical practice
Véronique Diéras, FR

My patient with HER2-positive metastatic breast cancer: What are my current treatment options?
Rupert Bartsch, AT

Adverse event awareness and management: Optimising patient outcomes
Andreas Charalambous, CY

My patient with HER2-positive metastatic breast cancer: What possibilities might there be in the future?
Véronique Diéras, FR

Panel discussion
Véronique Diéras, FR and Rupert Bartsch, AT and Andreas Charalambous, CY

Live Q&A: Friday 5 November 2021 17:30-17:45

Véronique Diéras, FR - Rupert Bartsch, AT - Andreas Charalambous, CY

Symposium faculty
Rupert Bartsch, Medical University Vienna, Vienna, AT
Andreas Charalambous, Cyprus University of Technology, Cyprus, CY
Véronique Diéras, Centre Eugène Marquis, Rennes, FR

 

 

Lilly sponsored satellite symposium
Beyond the doors of MDT meeting: impact on HR+HER2- breast cancer patients. Real world discussion

On-demand session (duration: 01h00):

Welcome and introduction
Miguel Martin, ES

Clinical case discussion: high risk ER+/HER2- early breast cancer
Presenter: Elisabetta Munzone, IT
Experts panel: Isabel Rubio, ES - Philip Poortmans, BE - Nicola Fusco, IT
Chair: Miguel Martin, ES

Clinical case discussion: de novo metastatic disease
Presenter: Carmen Criscitiello, IT
Experts panel: Isabel Rubio, ES - Philip Poortmans, BE - Nicola Fusco, IT
Chair: Miguel Martin, ES

Take home messages
Miguel Martin, ES

Symposium faculty
Carmen Criscitiello, IRCCS European Institute of Oncology (IEO), Milan, IT
Nicola Fusco, University of Milan, IRCCS European Institute of Oncology (IEO), Milan, IT
Miguel Martin, Hospital Universitario Gregorio Marañon, Madrid, ES
Elisabetta Munzone, IRCCS European Institute of Oncology (IEO), Milan, IT
Philip Poortmans, University of Antwerp, Wilrijk-Antwerp, BE
Isabel Rubio, Navarra University Clinic, Madrid, ES

 

  
Novartis sponsored satellite symposium
What matters to patients with HR+ HER2– ABC: Expanding options for living better for longer

 

On-demand session (duration: 01h30):

Opening remarks
Michelino De Laurentiis, IT

CDK4/6 inhibitors in HR+ HER2– ABC: Maximizing impact on overall survival and quality of life
Michelino De Laurentiis, IT - Victoria Harmer, UK

Discussion
Michelino De Laurentiis, IT - Christian Singer, AT - Victoria Harmer, UK

Personalizing treatment to ensure optimal benefit from PI3K inhibitors in HR+ HER2– ABC
Christian Singer, AT - Victoria Harmer, UK

Discussion
Michelino De Laurentiis, IT - Christian Singer, AT - Victoria Harmer, UK

Closing remarks
Michelino De Laurentiis, IT

Symposium faculty
Michelino De Laurentiis, National Cancer Institute “Fondazione Pascale”, Naples, IT
Christian Singer, Medical University of Vienna, Vienna, AT
Victoria Harmer, Imperial College Healthcare NHS Trust, London, UK

 



Pfizer sponsored satellite symposium
Raising awareness of underserved patient populations: Solutions from the real world

 

On-demand session (duration: 45min):

Welcome and introduction to underserved populations
Joanna Taylor, UK

Managing underserved patients in the real-world
Eduard Vrdoljak, HR - Etienne Brain, FR

Q&A and faculty discussion
Etienne Brain, FR - Joanna Taylor, UK - Eduard Vrdoljak, HR

Symposium faculty
Etienne Brain, René-Huguenin Hospital – Insitut Curie, Saint-Cloud, FR
Joanna Taylor, After Breast Cancer Diagnosis, Oldham, UK
Eduard Vrdoljak, University of Split and KGB Split, Split, HR

 

Live Q&A: Saturday 6 November 2021 13:30-13:45:
Etienne Brain, FR - Joanna Taylor, UK - Eduard Vrdoljak, HR

 



Seagen sponsored satellite symposium
Multidisciplinary team perspectives on the evolving treatment landscape in HER2+ MBC

 

On-demand session (duration: 45 min):

Introduction to the session - Filippo Montemurro, IT (Chair)

Welcoming our patient: What are the considerations for her management?

The disease of our patient progresses: How could emerging treatment options support her journey?

Our patient experiences brain metastases: What are her options?

Icro Meattini, IT  - Filippo Montemurro, IT - Doris Schmitt, DE

Live Q&A: Friday 5 November 2021 13:30-13:45

Icro Meattini, IT - Filippo Montemurro, IT - Doris Schmitt, DE

Symposium faculty
Icro Meattini, University of Florence, Florence, IT
Filippo Montemurro, Fondazione del Piemonte per l’Oncologia/Candiolo Cancer Institute Candiolo, IT
Doris Schmitt, Patient representative, DE